Journal Mobile Options
Table of Contents
Vol. 89, No. 3, 2012
Issue release date: October 2012
Urol Int 2012;89:307–310
(DOI:10.1159/000339920)

Ureteral Stenting in Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy as a Routine Procedure: Evidence and Necessity

Coccolini F. · Lotti M. · Manfredi R. · Catena F. · Vallicelli C. · De Iaco P.A. · Da Pozzo L. · Frigerio L. · Ansaloni L.
Departments of aGeneral and Emergency Surgery, bUrology, and cObstetrics and Gynecology, Ospedali Riuniti, Bergamo, and Departments of dGeneral and Transplant Surgery, and eObstetrics and Gynecology, Sant’Orsola-Malpighi University Hospital, Bologna, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Introduction: There is a need for more exhaustive data concerning the use of prophylactic ureteral stenting for extended debulking and cytoreductive procedures in the literature. Material and Methods: A retrospective analysis of the CARPEPACEM study protocol database was performed. The trial protocol schedules the positioning of bilateral ureteral stents before cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC). Results: Fifty-one operated patients: 31 (59.6%) with peritoneal dissemination from ovarian cancer, 8 (15.3%) from colorectal cancer, 4 (7.9%) from pseudomyxoma peritonei, 3 (5.7%) from gastric cancer, 2 (3.8%) from peritoneal mesothelioma, 1 (1.9%) from appendiceal cancer, 1 (1.9%) from endometrial cancer, and 1 (1.9%) from leiomyosarcoma. Mean and median peritoneal cancer index: 11 and 10 (range: 0–28). CC-score: CC-0 in 45 (86.5%) patients, CC-1 in 5 (9.6%) and CC-2 in 1 (1.9%). HIPEC was performed with platinum + taxol in 22 patients (42.3%), platinum + adriablastin in 10 (19.2%), mitomycin in 9 (17.3%), platinum + mitomycin in 7 (13.4%), platinum + doxorubicin in 2 (3.8%), and taxol + adriablastin in 1 (1.9%). Two major ureteral complications were observed (3.9%). Discussion: Prophylactic ureteral stenting could reduce the risk of postoperative ureteral complications without an increase in stent placement-related complications; however, a randomized clinical trial is needed.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Gilmour DT, Das S, Flowerdew G: Rates of urinary tract injury from gynecologic surgery and the role of intraoperative cystoscopy. Obstet Gynecol 2006;107:1366–1372.
  2. Chou M-T, Wang C-J, Lien RC: Prophylactic ureteral catheterization in gynecologic surgery: a 12-year randomized trial in a community hospital. Int Urogynecol J 2009;20:689–693.

    External Resources

  3. Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995;221:29–42.
  4. Sugarbaker PH: Review of a personal experience in the management of carcinomatosis and sarcomatosis. Jpn J Clin Oncol 2001;31:573–583.
  5. Dowling RA, Corriere JN, Sandler CM: Iatrogenic ureteral injury. J Urol 1986;135:912–915.
  6. Fry DE, Milholen L, Harbrecht PJ: Iatrogenic ureteral injury: options in management. Arch Surg 1983;118:454–457.
  7. Bothwell WN, Bleicher RJ, Dent TL: Prophylactic ureteral catheterization in colon surgery. Dis Colon Rectum 1994;37:330–334.
  8. Leff EL, Graff W, Rubin RJ, Eisenstat TE, Salvati EP: Use of ureteral catheters in colonic and rectal surgery. Dis Colon Rectum 1982;25:457–460.
  9. Redan JA, McCarus SD: Protect the ureters. JSLS 2009;13:139–141.
  10. Schimpf MO, Gottenger EE, Wagner JR: Universal ureter stent placement at hysterectomy to identify ureteral injury: a decision analysis. BJOG 2008;115:1151–1158.
  11. Ang C, Naik R: The value of ureteric stenting in debulkig surgery for disseminated ovarian cancer. Int J Gynecol Cancer 2009;5:978–980.

    External Resources

  12. Vakili B, Chesson RR, Kyle BL, et al: The incidence of urinary tract injury during hysterectomy: a prospective analysis based on universal cystoscopy. Am J Obstet Gynecol 2005;192:1599–1604.
  13. Sorinola O, Begum R: Prevention and management of ureteric injuries. Hosp Med (London) 2005;66:329–334.

    External Resources

  14. Dorairajan G, Rani PR, Habeebullah S, Dorairagan LN: Urologic injuries during hysterectomy (a six-year review). J Obstet Gynecol Res 2004;30:430–435.

    External Resources

  15. Mantani YS, Bani-Hani KE, Bani-Hani IH: Ureteric injuries during obstetric and gynecologic procedures. Saudi Med J 2003;24:3565–3568.
  16. Ostrzenski A, Rodolinski B, Ostrzenska KM: A review of laparoscopic ureteral injuries in pelvic surgery. Obstet Gynecol Surv 2003;58:794–799.

    External Resources

  17. Liapis A, Bakas P, Giannopoulos V, Creatsas G: Ureteral injuries during gynecologic surgery. Int Urogynecol J 2001;12:391–393.
  18. Smeenk RM, Bex A, Verwaal VJ, Horenblas S, Zoetmulder FAN: Pseudomyxoma peritonei and the urinary tract involvement and treatment related complications. J Surg Oncol 2006;93:20–23.
  19. Kumar A, Verma BS, Srivastava A, Bhandari M, Gupta A, Sharma R: Evaluation of the urological complications of living related renal transplantation at a single center during the last 10 years: impact of the double J stent. J Urol 2000;164:657–660.
  20. Mangus RH, Haag BW: Stented versus non-stented extravesical ureteroneocystostomy in renal transplantation: a metaanalysis. Am J Transplant 2004;4:1889–1896.
  21. Nie ZL, Zhang QS, Jin FS, Zhu FQ, Huo WQ: Treatment of urinary fistula after kidney transplantation. Transplant Proceed 2009;41:1624–1626.

    External Resources

  22. Shingleton HM: Repairing injuries of the urinary tract: update on general surgery. Contemp Obstet Gynecol 1984;23:76–90.
  23. Kuno K, Menzin A, Kauder HH, Sison C, Gal D: Prophylactic ureteral catheterization in gynaecologic surgery. Urology 1998;52:1004–1008.
  24. Watterson JD, Mahoney JE, Futter NG, Gaffield J: Iatrogenic ureteric injuries: approaches to etiology and management. Can J Surg 1998;41:379–382.
  25. Bothwell WN, Bleicher RJ, Dent TL: Prophylactic ureteral catheterization in colon surgery. A five-year review. Dis Colon Rectum 1994;37:330–334.
  26. Kyzer S, Gordon PH: The prophylactic use of ureteral catheter dirung colorectal operations. Am Surg 1994;60:212–216.
  27. Quinlan DJ, Townsend DD, Johnson GH: Are ureteral catheter in gynecologic surgery beneficial or hazardous? J Am Assoc Gynecol Laparosc 1995;3:61–65.
  28. Coccolini F, Ansaloni L, Concetti S, Schiavina R, Martorana G: The importance of ureteral stenting in major debulking surgery. Int J Gynecol Cancer 2010;20:479.

    External Resources

  29. Saltzman B: Ureteral stent: indications, variations and complications. Urol Clin North Am 1988;15:481–491.
  30. Westenfelder M, Rosset K, Peltz K: Development of nosocomial and iatrogenic urinary tract infections (UTI) following urological interventions. A prospective clinical study. Scand J Urol Nephrol Suppl 1987;104:59–63.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00